Actuate Therapeutics Inc [ACTU] stock prices are down -2.23% to $6.59 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The ACTU shares have gain 13.23% over the last week, with a monthly amount drifted -32.41%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Actuate Therapeutics Inc [NASDAQ: ACTU] stock has seen the most recent analyst activity on April 22, 2025, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $21. Previously, H.C. Wainwright started tracking the stock with Buy rating on March 17, 2025, and set its price target to $20.
The stock price of Actuate Therapeutics Inc [ACTU] has been fluctuating between $5.50 and $11.99 over the past year. Currently, Wall Street analysts expect the stock to reach $21 within the next 12 months. Actuate Therapeutics Inc [NASDAQ: ACTU] shares were valued at $6.59 at the most recent close of the market. An investor can expect a potential return of 218.66% based on the average ACTU price forecast.
Analyzing the ACTU fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -5.64, Equity is 0.89 and Total Capital is 5.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.30 points at the first support level, and at 6.02 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.83, and for the 2nd resistance point, it is at 7.08.
Ratios To Look Out For
It’s worth pointing out that Actuate Therapeutics Inc [NASDAQ:ACTU]’s Current Ratio is 0.46. On the other hand, the Quick Ratio is 0.46, and the Cash Ratio is 0.42.
Transactions by insiders
Recent insider trading involved Bios Equity COF, LP, Director, that happened on Jun 27 ’25 when 71428.0 shares were purchased. Director, Kreis Leslie W. completed a deal on Jun 27 ’25 to buy 71428.0 shares. Meanwhile, Director Fletcher Aaron G.L. bought 71428.0 shares on Jun 27 ’25.
